$CVKD

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to 2022 Successor Equity Incentive Plan On September 24, 2026, Cadrenal Therapeutics, Inc. (the “Company”), held

U.S. stock futures eased after a strong H1 rally, with Dow up about 8.9%, S&P 500 up 9.6%, Nasdaq up 12.8%, and Russell 2000 up about 22%. Traders look ahead to ADP and Thursday’s nonfarm payrolls for Fed signals. Several stocks moved premarket: NKE -4%, TSLA deliveries ~410k expected, NIO -4%, MU -4%, LUNR +8%, ASTS +20%, CVKD -16%.

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio org

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029808201ex10-1.htm CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE, DATED AS OF JULY 9, 2026, BY AND BETWEEN CADRENAL THERAPEUTICS, INC. AND JAMES J. FERGUSON III Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Ag

Cadrenal Therapeutics (Nasdaq: CVKD) said Phase 2 late-breaking data for its 12-LOX inhibitor CAD-1005 were presented at ISTH 2026. In HIT, CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events vs placebo (50% vs >75%) and no CAD-1005-attributable serious adverse events or deaths. Company cites $2B peak annual revenue potential.

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001937993 0001937993 2026-07-07 2026-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029666601ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT, DATED JUNE 30, 2026, BY AND BETWEEN CADRENAL THERAPEUTICS, INC. AND THE PURCHASER NAMED THEREIN Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of

Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029632801ex10-1.htm MASTER SERVICES AGREEMENT, DATED AUGUST 21, 2024, BETWEEN THE COMPANY AND LOHMAN & ASSOCIATES, INC Exhibit 10.1 MASTER SERVICES AGREEMENT This Master Services Agreement (this “ Agreement ”) is entered into as of August 21, 2024 (the “ Effective Dat

Cadrenal Therapeutics said it plans to file for FDA Rare Pediatric Disease designation for tecarfarin in children with Kawasaki disease who develop coronary artery aneurysms. The company says tecarfarin is designed to provide more stable anticoagulation than warfarin. If approved, Cadrenal could receive a Priority Review Voucher, which it notes has sold for $180M–$205M.

Pham Quang X (CEO and Chairman) sold 1,165 shares of Cadrenal Therapeutics, Inc. (CVKD) at $5.69 on 2026-05-22 under a Rule 10b5-1 trading plan.